The dietary supplement industry is facing mounting pressure from regulators, retailers, and independent watchdogs, prompting companies to overhaul quality standards, pursue third-party certifications, and engage with proposed federal legislation. The scrutiny arrives as the market has expanded from roughly 4,000 products in 1994 to more than 80,000 today, straining existing oversight frameworks.
SuppCo recently launched its “TESTED by SuppCo” certification program, anonymously purchasing supplements and submitting them to ISO 17025-accredited laboratories. Products must meet or exceed 95% of their labelled active ingredient claims to qualify. Initial partners include Momentous, Thorne, Metagenics, and Gaia Herbs. The program publishes all results publicly, including failures — a significant step given that prior testing found roughly half of top-selling supplements did not meet label accuracy standards.
Regulatory enforcement has also intensified. The FDA issued warning letters to companies including CC Pollen Company and Eniva USA, citing adulterated products, failure to establish product specifications, and unapproved drug claims. These actions fall under DSHEA enforcement and align with the agency’s Human Foods Program priorities for 2026.
Separately, an EU customs operation examined nearly 3,500 supplement shipments from non-EU sellers and found widespread violations, including incorrect labelling, missing documentation, and forbidden ingredients. The UK was identified as the primary source of non-compliant products, signalling heightened risk for British exporters.
On the legislative front, Senator Dick Durbin reintroduced the Dietary Supplement Listing Act on January 15, 2026. The bill would require manufacturers to submit product names, ingredients, and labels to the FDA, creating a publicly searchable database without imposing premarket approval. The Council for Responsible Nutrition, Consumer Federation of America, USP, and USPIRG have expressed support.
Trade groups remain active on several fronts. The CRN is pushing for federal preemption to prevent inconsistent state regulations, while the NPA is challenging FDA decisions to exclude NAC and NMN from supplement classifications. The FDA has also scheduled a public meeting on March 27, 2026 to discuss the scope of dietary supplement ingredients under DSHEA, a development that trade groups and manufacturers are closely monitoring.
Meanwhile, national retailers are demanding reformulations, third-party certifications, and supply chain transparency. Manufacturers are simultaneously maneuvering through 21 CFR Part 111 requirements, validating potency, mixing uniformity, and shelf-life stability across increasingly complex product formulations.
